Improved analytical methods for measuring urinary phthalate metabolites have resulted in biomarker-based estimates of phthalate daily intake for the general population, but not for occupationally exposed groups. In 2003-2005, we recruited 156 workers from eight industries where materials containing diethyl phthalate (DEP), dibutyl phthalate (DBP), and/or di(2-ethylhexyl) phthalate (DEHP) were used as part of the worker's regular job duties. Phthalate metabolite concentrations measured in the workers' end-shift urine samples were used in a simple pharmacokinetic model to estimate phthalate daily intake. DEHP intake estimates based on three DEHP metabolites combined were 0.6-850 mg/kg/day, with the two highest geometric mean (GM) intakes in polyvinyl chloride (PVC) film manufacturing (17 mg/kg/day) and PVC compounding (12 mg/kg/day). All industries, except phthalate manufacturing, had some workers whose DEHP exposure exceeded the U.S. reference dose (RfD) of 20 mg/kg/day. A few workers also exceeded the DEHP European tolerable daily intake (TDI) of 50 mg/kg/day. DEP intake estimates were 0.5-170 mg/kg/day, with the highest GM in phthalate manufacturing (27 mg/kg/day). DBP intake estimates were 0.1-76 mg/kg/day, with the highest GMs in rubber gasket and in phthalate manufacturing (17 mg/kg/day, each). No DEP or DBP intake estimates exceeded their respective RfDs. The DBP TDI (10 mg/kg/day) was exceeded in three rubber industries and in phthalate manufacturing. These intake estimates are subject to several uncertainties; however, an occupational contribution to phthalate daily intake is clearly indicated in some industries.
Introduction
Phthalates are used as plasticizers in polyvinyl chloride (PVC) plastics, as lubricants in certain rubbers (e.g. nitrile and neoprene), and as fixatives (or carriers) in perfumes and fragrances (Stanley et al., 2003; Wypych, 2004) . Phthalates are not covalently bound to polymeric materials and can migrate to the environment over time resulting in human exposure. Sources of phthalate exposure include the workplace, diet, off-the-job activities, personal care products, and other home or environmental sources. Phthalates have been evaluated as possible reproductive and developmental toxicants in animals and humans (Hauser and Calafat, 2005; Latini, 2005; Heudorf et al., 2007; Matsumoto et al., 2008) and may also have a function in respiratory disease (Bornehag et al., 2004; Hoppin et al., 2004; Jaakkola and Knight, 2008; Kolarik et al., 2008) .
Sensitive and specific analytical methods have been developed over the past decade to measure concentrations of phthalate metabolites in urine (Koch et al., 2003a; Itoh et al., 2005; Kato et al., 2005; Preuss et al., 2005; Silva et al., 2007 Silva et al., , 2004 . Phthalate urinary metabolite concentrations can be used in simple pharmacokinetic models to estimate daily intake (David, 2000; Kohn et al., 2000) . These models assume steady state excretion of metabolites and a constant daily creatinine excretion (CE) rate, conditions that depend on the temporal variability of the phthalate exposure and the characteristics of the sampled individual. When multiple individuals are monitored in a given exposure setting, some of this temporal variability may be accounted for by averaging intake estimates across the group.
Intake estimates can be useful for risk assessment by comparing them to chronic oral reference doses (RfDs) established by the U.S. Environmental Protection Agency (EPA) (U.S. EPA, 2007a,b,c,d) and to tolerable daily intakes (TDIs) established by the European Food Safety Authority (EFSA). (EFSA (European Food Safety Authority), 2005a, b, c). The RfD (or TDI) is an estimate of the daily exposure to the human population (including sensitive subgroups) that is likely to be without appreciable risk of deleterious effects during a lifetime.
Biomonitoring for phthalate exposure offers the advantages of integrating exposure across all routes (e.g. inhalation, dermal, ingestion). Moreover, as phthalates are ubiquitous in the environment, biomonitoring of metabolites largely avoids problems associated with the contamination of collection materials and analytical systems with parent compounds used in products. A recent study comparing different approaches for estimating human exposure to phthalates recommended using high quality measured concentrations in exposure media or back-calculation of intake from urinary metabolites (Franco et al., 2007) .
Biomarker-based estimates of phthalate daily intake are available for adults and children in the United States, Germany, Korea, Japan, and Taiwan (David, 2000; Kohn et al., 2000; Koo et al., 2002; Clark et al., 2003; Itoh et al., 2005; Koo and Lee 2005; Itoh et al., 2007; Koch et al., 2007 Koch et al., , 2006 Koch et al., , 2003b Wittassek et al., 2007; Chen et al., 2008; Wittassek and Angerer, 2008) , for pregnant women (Marsee et al., 2006) and for infants in neonatal intensive care units (Calafat and McKee, 2006; Weuve et al., 2006) ; however, phthalate daily intake estimates for occupationally exposed groups are lacking. In 2003-2005, the National Institute for Occupational Safety and Health (NIOSH) conducted a preliminary study of phthalate exposures among 156 workers in eight industry sectors where materials containing diethyl phthalate (DEP), dibutyl phthalate (DBP), and di(2-ethylhexyl) phthalate (DEHP) were manufactured or used as part of the workers' regular job duties. Exposure was assessed by measuring urinary metabolite concentrations.
In the human body, phthalates are rapidly metabolized and excreted into the urine (Hauser and Calafat, 2005) . Phthalates are initially hydrolyzed to their corresponding monoesters. Some monoesters are further metabolized to several oxidative metabolites. Monoester and oxidative metabolites may be glucuronidated before excretion. We used the monoester metabolites, monoethyl phthalate (MEP), and monobutyl phthalate (MBP), respectively, as markers of DEP and DBP exposure. Exposure to DEHP was monitored using its hydrolytic monoester, mono(2-ethylhexyl) phthalate (MEHP), and three oxidative metabolites, mono (2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), and mono(2-ethyl-5-carboxypentyl) phthalate (MECPP). Although we were primarily interested in DEP, DBP, and DEHP exposure, the analytical method we used also captured metabolites of diisobutyl phthalate (DiBP) and benzylbutyl phthalate (BzBP).
We previously reported urinary phthalate metabolite concentration data for workers in the surveyed industries manufacturing or using the target phthalates as part of their regular job duties and evaluated the likelihood of an occupational contribution to these concentrations (Hines et al., 2009) . In this article, we use these data to generate worker daily intake estimates by industry sector, compare estimates to U.S. and European reference values, and discuss methodological limitations.
Methods

Study Population
We recruited 156 participants in 2003-2005 from eight phthalate-using sectors as described earlier (Hines et al., 2009) . These sectors included one company from each of seven manufacturing sectors: phthalate manufacturing, PVC film, PVC compounding, vehicle filters, rubber hoses, rubber gaskets, and rubber boots, and 13 companies from one service sector: nail-only salons. Recruited participants worked in jobs or on processes where DEP, DBP, and/or DEHP were manufactured or used (Table 1) . Participation was voluntary and informed consent was obtained. This study was approved by the NIOSH Human Subjects Review Board.
The sectors have been described earlier (Hines et al., 2009 ). In brief, dimethyl phthalate, DEP, DBP, and DEHP were produced as raw materials in phthalate manufacturing by the addition of alcohols to phthalic anhydride in the presence of a catalyst. The PVC film sector produced sheets of PVC film using either DEHP or diisononyl phthalate (DiNP) as plasticizers. In PVC compounding, custom-formulated PVC pellets were produced using DEHP, DiNP, or ditridecyl phthalate as plasticizers. In the production of vehicle filters, a plastisol (a dispersion of resin and plasticizer) containing DEHP was dispensed onto filter end-caps, followed by convection oven curing. Three sectors manufactured neoprene and nitrile rubber products containing phthalates (rubber hose: DBP, DEHP, and di-n-octyl phthalate; rubber gasket: DBP and DiBP; rubber boot: DEHP). Nail-only salons provided manicure, pedicure, and artificial nail services using nail care products containing DBP.
Sample Collection and Analysis
Each participant collected an end-shift urine sample during a single work shift without regard to day of the week in 125 ml sterile polypropylene specimen cups prescreened for phthalates. We analyzed samples for phthalate metabolites using an analytical approach involving enzymatic deconjugation of the metabolites from their glucuronidated form, automated solid-phase extraction, separation with high performance liquid chromatography, and detection by isotope-dilution tandem mass spectrometry Kato et al., 2005) . Each analytical run also included calibration standards, reagent blanks, and quality control materials. Analysts were blind to all participant information. We also analyzed each sample for creatinine (Hines et al., 2009 ).
Daily Intake Estimates
We used end-shift creatinine-adjusted concentrations and the method of David (2000) (Eq. 1) to estimate each participant's daily intake of DEP, DBP, DEHP, BzBP, and DiBP.
The David (2000) method is a variation of a linear twocompartment model initially used by Kohn et al. (2000) . Equation 1 assumes steady-state excretion. Marsee et al. (2006) found close agreement between the David (2000) and Kohn et al. (2000) models.
UE (urinary excretion) is the urinary concentration of the metabolite adjusted for creatinine, CE is the daily creatinine excretion rate normalized by body weight and is set at 23 mg/ kg/day and 18 mg/kg/day for men and women, respectively (Harper et al., 1977; Kohn et al., 2000; Wallach, 2000) , F UE (fractional urinary excretion) is the molar fraction of excreted metabolite relative to total intake at 24-h post-dosing, and MW d /MW m is the molecular weight ratio of diester to metabolite. F UE values for MBP (0.69) and monobenzyl phthalate (MBzP, 0.73) were taken from published human data (Anderson et al., 2001) . F UE values for MEP and monoisobutyl phthalate (MiBP) were set to that of MBP (Kohn et al., 2000; Koch et al., 2003b) .
DEHP daily intake was estimated using three or four DEHP metabolites combined and F UE values based on human data ( (Koch et al., 2005a) . We converted creatinine-adjusted metabolite concentrations to moles per gram before summing. We had MEHP, MEHHP, and MEOHP concentration data in all eight sectors, but MECPP concentrations in only four, as the capability to analyze for MECPP was not available until midway through the study.
DI ðmg=kg=dayÞ ¼
Total DEHP metabolites ðmoles=gÞÂCE ðmg=kg=dayÞÂMWDEHPÂ1000 ðmg=mgÞ
We estimated DBP daily intake separately using MBP alone or MBP and MiBP combined. Current RfDs and TDIs for DBP do not distinguish between the two isomers (Marsee et al., 2006) . We estimated BzBP and DiBP daily intake using their respective monoesters only. Only 6% of ingested BzBP is excreted as MBP (Anderson et al., 2001 ); therefore, MBzP was considered the principal BzBP metabolite.
Data Analysis
The distribution of the phthalate daily intake estimates was skewed to the right (suggesting log-normality) and therefore a natural log transformation was applied to the estimates. Analyses were performed in SAS vs 9.1 (SAS Institute, Cary, NC, USA). We estimated the geometric mean (GM) and geometric standard deviation (GSD) of the daily intake estimates for each sector. Left censoring at the limit of detection (LOD) was generally low (i.e. o12%) for all metabolites, except for MzBP in nail-only salons (32% oLOD). For left-censored data, we used maximum likelihood estimation (MLE) in the LIFEREG procedure to estimate the GM and GSD. Where use of MLE was not feasible (i.e. where metabolites were summed (MEHP3 and MEHP4) and in Figure 1 ), we imputed one-half of the LOD.
To test for differences in intake estimates across sectors (sector effect), we performed a one-way analysis of variance using the NLMIXED procedure and Bonferroni's adjustment for multiple comparisons. We also computed the proportion of DEP, DBP, BzBP, and DEHP daily intake estimates greater than their respective RfDs and TDIs by sector. Statistical significance was set at a ¼ 0.05.
Results
Participants included 114 (73%) men and 42 (27%) women. Demographics have been described earlier (Hines et al., Estimated daily intake of phthalates in occupationally exposed groups Hines et al.
2009
). Briefly, most participants were white (51%) or Hispanic (27%). Mean (±SD) participant age was 38 (±12) years. Estimated daily intakes for DEP, DBP, DiBP, BzBP, and DEHP are summarized by sector in Table 2 and in Figure 1 .
DEP DEP daily intake estimates ranged from 0.5 to 170 mg/kg/day (Table 2) . DEP GM intake estimates varied significantly by sector (Po0.0001). Phthalate manufacturing, which produced DEP, had the highest sector GM estimate (27 mg/kg/ day). In all other sectors, DEP GM intake estimates (2.2-6.7 mg/kg/day) were several-fold lower than in phthalate manufacturing. None of the DEP daily intake estimates exceeded the RfD (800 mg/kg/day), and most intake estimates were o25% of the RfD. A TDI has not been established for DEP.
DBP
DBP daily intake estimates ranged from 0.1 to 76 mg/kg/day (Table 2) . GM DBP intake estimates differed significantly by sector (Po0.0001) and were highest in rubber gasket (17 mg/ kg/day), phthalate manufacturing (17 mg/kg/day), and rubber hose (6.9 mg/kg/day). All other sectors had GM intake estimates o2 mg/kg/day. When MiBP was combined with MBP, the increase in the GM DBP intake estimate for all sectors was o1 mg/kg/day, with most increases o0.5 mg/kg/day.
None of the DBP intake estimates exceeded the DBP RfD (100 mg/kg/day). Most DBP intake estimates were o25% of the RfD; the highest estimate (in rubber hose) was 76% of the RfD. Four sectors had sampled workers whose DBP intake estimates (based on MBP alone) exceeded the TDI (10 mg/kg/day): phthalate manufacturing (67%); rubber hose (32%), rubber boot (5%), and rubber gasket (80%). Phthalate manufacturing produced DBP, and rubber gasket, and rubber hose each produced neoprene and nitrile rubber products containing DBP; however, we are not aware of a DBP source in rubber boot.
DiBP
DiBP daily intake estimates ranged over several orders of magnitude (0.02-32 mg/kg/day) ( Table 2) . GM DiBP estimates were significantly different by sector (Po0.0001 each) and were highest in the rubber sectors: rubber boot (0.37 mg/ kg/day); rubber hose (0.31 mg/kg/day), and rubber gasket The dotted horizontal line is the EFSA tolerable daily intake (TDI). In these plots, the LOD divided by two was used for observations below the LOD. Sector abbreviations: manf, phthalate manufacturing; film, PVC film, filt, vechicle filters; cmpd, PVC compounding; hose, rubber hose; boot, rubber boot; gask, rubber gasket; nail, nail-only salons.
(0.31 mg/kg/day). Neither an RfD nor a TDI has been established for DiBP. The highest individual worker estimate (32 mg/kg/day) was in rubber hose, although DiBP use was not reported at the facility.
BzBP
BzBP daily intake estimates varied by 2-3 orders of magnitude (0.02-17 mg/kg/day) ( Table 2 ). BzBP GM estimates were o3 mg/kg/day in all sectors. Rubber gasket had the highest individual BzBP estimate (17 mg/kg/day); this intake was o10% of the RfD (200 mg/kg/day) and o5% of the TDI (500 mg/kg/day). No company reported using BzBP, therefore, these estimates may reflect only background BzBP exposure.
DEHP
DEHP daily intake estimates varied 41000-fold (MEHP3: 0.6-850 mg/kg/day) ( Table 2) . Variability was generally less within-than across-sectors. GM DEHP intake estimates varied by approximately four-fold across sectors (MEHP3: Hines et al., 2009. 4.3-17 mg/kg/day), and differed significantly by sector (Po0.0001). PVC film and PVC compounding, two PVC sectors that used DEHP, had the highest GM DEHP intake estimates based on MEHP3 (17 and 12 mg/kg/day, respectively).
All sectors, except phthalate manufacturing, had some fraction of sampled workers whose intake estimates (based on MEHP3) exceeded the RfD (Table 2; Figure 1 ). The exceedance fractions were highest for PVC compounding (50%) and PVC film (32%), and o15% in the remaining sectors, a figure that may be within the uncertainty of the estimation method. Generally, fewer workers in each sector exceeded the DEHP TDI (50 mg/kg/day), which is 2.5 times higher than the RfD (Table 2 ).
Discussion
Heretofore, biologically based estimates of phthalate daily intake have been limited to non-occupationally exposed populations. Our earlier report (Hines et al., 2009 ) of urinary phthalate metabolite concentrations in eight workplace sectors was a first step toward understanding workers' risk from phthalate exposure. Additional steps include estimating daily intake, comparing estimates to reference values, and ultimately evaluating exposure-response relationships in human populations. In this article, we report daily intake estimates for DEP, DBP, DiBP, BzBP, and DEHP among workers in eight sectors where DEP, DBP, and/or DEHP were manufactured or used as part of the workers' regular job duties.
Not surprisingly, use of a specific phthalate in a sector often, but not always, coincided with an increased intake estimate as compared with sectors not using the phthalate. For example, use of DEP and DBP in a sector (with the exception of the nail technicians) corresponded well with elevated DBP intake estimates. Nail technicians handle small quantities of DBP in lacquer-type materials at room temperature. DBP is unlikely to vaporize from these nail products, thus reducing the opportunity for inhalation exposure. Also, nail products are not typically applied to the technician's skin. The correspondence of DEHP use in a sector with DEHP intake estimates is more likely influenced by heated processes, large open heated surface areas, and large quantities of DEHP used. The two PVC sectors with the highest DEHP intake estimates had some or all of these conditions. The other DEHP-using sectors may have had a few workers on jobs with these process characteristics, but the majority of persons worked with DEHP under either more controlled conditions or conditions less likely to release DEHP.
Our phthalate daily intake estimates for workers can be compared with published estimates for non-occupationally exposed populations where the David (2000) method was used. DEP intake estimates for workers in phthalate manufacturing (GM ¼ 27 mg/kg/day) that produced DEP were 4-5-fold higher than U.S. pregnant women (Marsee et al., 2006 ) (median ¼ 6.64 mg/kg/day) and a subset of U.S. adults and children in the National Health and Nutrition Examination Survey (NHANES) 1999 (Clark et al., 2003) (GM ¼ 5.42 mg/kg/day); DEP intake estimates for workers in the remaining sectors were similar to these two groups.
DBP daily intake estimates for workers in our two highest DBP-exposed sectors, phthalate manufacturing, and rubber gasket (GM ¼ 17 mg/kg/day, each), were 4-to 20-fold higher than estimates for a subset of U.S. adults and children in NHANES 99 (GM ¼ 0.90 mg/kg/day) (Clark et al., 2003) , U.S. pregnant women (median ¼ 0.84 mg/kg/day) (Marsee et al., 2006) , German children (median ¼ 4.07 mg/kg/day) and German adults and children (median ¼ 2.1 mg/kg/day) (Wittassek and Angerer, 2008) ; however, our highest individual DBP intake estimate (76 mg/ kg/day) was lower than for some people using medications with coatings containing DBP (Herna´ndez-Diaz et al., 2009) DEHP daily intake has been estimated using different DEHP metabolites (Calafat and McKee, 2006; Koch et al., 2006 Koch et al., , 2005b Weuve et al., 2006; Wittassek and Angerer, 2008) . DEHP intake estimates (based on MEOHP only) reported for infants in a neonatal intensive care unit (Weuve et al., 2006) (median ¼ 325 mg/kg/day) and for premature neonates (Calafat and McKee, 2006 ) (GM ¼ 1256 mg/kg/ day) were 1-2 orders of magnitude higher than for workers in our most highly exposed sector (PVC film, GM ¼ 16 mg/kg/ day, based on MEOHP only, data not shown). In PVC film and PVC compounding, DEHP intake estimates (based on MEHP3) were B2-6-fold higher than in German adults and children (Koch et al., 2006; Wittassek and Angerer, 2008) , but approximately half that of platelet donors highly exposed to DEHP leaching from PVC materials used during apheresis (Koch et al., 2005b) .
Workplace air sampling data have also been used to estimate worker phthalate daily intake. Using published air sampling data, and assuming 10 m 3 of air inhaled during a work shift, a body weight of 70 kg, and a 5-day work week, Huber et al. (1996) estimated mean DEHP daily intake in PVC processing at 12-26 mg/kg/day (data from Dirven et al. (1993) ) and o2-30 mg/kg/day (data from Vainotalo and Pfa˜ffli (1990) ), pipe coating with DEHP-based plastisol at 10 mg/kg/day (data from NIOSH (1979)), and phthalate manufacturing at 7.1 mg/kg/day (data from Liss et al. (1985) ). GM daily intake estimates in our PVC-processing operations, PVC film (17 mg/kg/day) and PVC compounding (12 mg/kg/day), were comparable to the air sample-based estimates. The GM daily intake estimate in vehicle filter (6.9 mg/kg/day), which used a DEHP plastisol, was B30% lower than the air sample-based estimate for pipe-coating. Our estimate of DEHP daily intake in phthalate manufacturing was approximately half of the air sample-based estimate.
Estimating phthalate daily intake based on biological monitoring data and the relatively simple pharmacokinetic model we used entails a number of uncertainties, including temporal variability in metabolite concentrations, source variability (e.g. changes in work processes and emission rates), variability in certain model input parameters (i.e. F UE and CE), within-and between-person metabolic variability, and variability due to exposure route. Our daily intake estimates were based on end-shift urine samples; however, phthalate exposure can fluctuate within the work day (Hines et al., 2009) , between work-and non-work periods within-aday, and from day-to-day. Moreover, depending on the timing and intensity of phthalate exposure during work, workers could excrete metabolites for some time after leaving work. Nonetheless, with 9-25 workers per sector, some of this temporal variability was likely averaged across workers. Temporal variability in metabolite concentrations is further heightened by the metabolites' relatively short half-lives and rapid elimination in the urine (Anderson et al., 2001; Api, 2001; Koch et al., 2005a Koch et al., , 2004 . Within-person variability in urinary phthalate metabolite concentrations has been shown to depend on the population, phthalate metabolite, and time frame of interest (Hoppin et al., 2002; Hauser et al., 2004; Fromme et al., 2007; Teitelbaum et al., 2008) . The degree of temporal variability has implications for using a single urine sample to predict phthalate exposures over a specified time. A 24-h urine sample may be preferable when within-day variability is high. The above factors illustrate the importance of population-specific studies to assess temporal variability of phthalate urinary biomarkers over relevant exposure periods.
The effects of exposure route, individual differences in metabolism, and dose-dependent differences in metabolism on F UE values are largely unknown. Our workers were most likely exposed to phthalates by inhalation or dermal contact. Koch et al. (2005a) found no dose dependency in DEHP metabolism and excretion (dose range: 4.7 to 650 mg/kg). Although one of our workers had a DEHP daily intake estimate 4800 mg/kg/day, 95% of our workers had DEHP estimates that were o70 mg/kg/day.
CE is also subject to uncertainty. CE is reported to range from 19 to 26 mg/kg/day in men and from 14 to 21 mg/kg/ day in women, an accuracy of B10-20% (Wallach, 2000) . Empirically based regression equations for adults using height, body weight, and gender have also been used for estimating CE (Kawasaki et al., 1991; Itoh et al., 2005 Itoh et al., , 2007 . The values we applied, 23 mg/kg/day (men) and 18 mg/kg/day (women), have been commonly used in the David (2000) model (Koo and Lee, 2005; Koch et al., 2006; Marsee et al., 2006; Chen et al., 2008) .
Racial/ethnic differences in CE are also possible. Creatinine concentrations in spot urine samples from NHANES III were significantly higher among non-Hispanic blacks as compared with other racial/ethnic groups (Barr et al., 2005) ; however, race/ethnicity was confounded within sector in our study (Hines et al., 2009) . Demographic characteristics such as education, family income, and place of residence have also been associated with concentrations of certain urinary phthalate metabolites in a subset of NHANES III participants (Koo et al., 2002) .
In the absence of occupational exposure standards, we compared our phthalate intake estimates to U.S. EPA RfDs and European TDI's. These reference values may not be entirely appropriate for workers who are usually considered to be ''healthier'' than the general population; however, workers may include pregnant women, a sensitive subgroup. Workers may also be exposed over shorter, more intense time periods (i.e. 40-60 h/week, 4-6 days/week) than is presumed for the general population. Sectors with Z25% of sampled workers exceeding the RfD for DEHP and the TDI for DBP used these phthalates in heated processes or in heated materials with large surface areas (Hines et al., 2009) .
Certain other study limitations should be noted. We recruited a convenience sample of likely phthalate exposed workers from interested companies. Therefore, our results were not intended to be representative of all workers in each company, of all companies in each sector, nor of all work sectors using the target phthalates. We also had no information on off-the-job activities, use of personal care products, materials in the home environment, diet, medical procedures or medications. Phthalate exposures from these other sources could have contributed to the observed urinary concentrations.
In summary, all sectors except phthalate manufacturing had workers whose DEHP daily intake estimates exceeded the DEHP RfD, with exceedance fractions highest in PVC film and PVC compounding. No sampled workers in any sector had daily intake estimates that exceeded the RfD for DEP, DBP, or BzBP; however, some workers in rubber gasket, phthalate manufacturing, rubber hose, and rubber boot (to a lesser extent) had DBP estimates greater than the 10-fold lower TDI. These results should be considered preliminary and are subject to a number of uncertainties. Additional occupational exposure monitoring studies with multiple, timed urine collections over several days pre-, during-, and post-exposure are needed to develop more sophisticated pharmacokinetic models for workers than the model used here. Nonetheless, our study offers the first biologically based intake estimates for workers, thus enabling us to better understand where workers fall in the human phthalate exposure continuum.
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